VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2021 | “Off-the-shelf” CAR-T: future prospects

Stephan Grupp, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, discusses the potential of having “off-the-shelf” chimeric antigen receptor T-cell (CAR-T) therapies, outlining existing studies and results so far, and highlighting the need for increased lymphodepletion when using allogeneic CAR T-cells. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.


Dr Stephan Grupp, MD, PhD, has received research support from Novartis, Servier, Vertex and Kite; and has participated in study steering committees, consulting, or scientific advisory boards with Novartis, Allogene, Adaptimmune, TCR2, Cabaletta, Juno, CBMG, GlaxoSmithKline, Cellectis, Johnson & Johnson/Janssen, CRISPR/Vertex, Roche, Humanigen and Jazz.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter